The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
The direct-to-consumer brand introduces its highly anticipated flagship chair with auto-tracking lumbar technology, now available for exclusive early reservation. LOS ANGELES, June 29,...
SHANGHAI, June 28, 2026 /PRNewswire/ -- AGIBOT, a global leader in embodied AI and robotics, today announced that its 15,000th robot has officially rolled...
SHANGHAI, June 28, 2026 /PRNewswire/ -- AGIBOT, a global leader in embodied AI and robotics, today announced that its 15,000th robot has officially rolled...
HONG KONG and SHANGHAI, June 28, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group"; HKEX:...
A category-defining upgrade for the front door — much like how Tesla redefined automotive energy, the V150 Plus introduces a new era of low-maintenance,...
A category-defining upgrade for the front door — much like how Tesla redefined automotive energy, the V150 Plus introduces a new era of low-maintenance,...
